Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ziopharm Oncology Inc.

www.ziopharm.com

Latest From Ziopharm Oncology Inc.

Tech Transfer Roundup: OncoSec Will Investigate CAR-T In Breast Cancer With Dana-Farber

Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.

Deals Business Strategies

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific

Deals Shaping The Medical Industry, June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

Deals BioPharmaceutical

Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds

Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ziopharm Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ziopharm Oncology Inc.
  • Senior Management
  • Laurence J Cooper, PhD, CEO
    Sath Shukla, CFO
    David Mauney, MD, Pres.
  • Contact Info
  • Ziopharm Oncology Inc.
    Phone: (617) 259-1970
    1 First Ave., Parris Bldg. #34
    Navy Yard Plaza
    Boston, MA 02129
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register